Cdc7 activates replication checkpoint by phosphorylating the Chk1 binding domain of Claspin in human cells

  1. Chi-Chun Yang
  2. Hiroyuki Kato
  3. Mayumi Shindo
  4. Hisao Masai  Is a corresponding author
  1. Tokyo Metropolitan Institute of Medical Science, Japan

Abstract

Replication checkpoint is essential for maintaining genome integrity in response to various replication stresses as well as during the normal growth. The evolutionally conserved ATR-Claspin-Chk1 pathway is induced during replication checkpoint activation. Cdc7 kinase, required for initiation of DNA replication at replication origins, has been implicated in checkpoint activation but how it is involved in this pathway has not been known. Here, we show that Cdc7 is required for Claspin-Chk1 interaction in human cancer cells by phosphorylating CKBD (Chk1-binding-domain) of Claspin. The residual Chk1 activation in Cdc7-depleted cells is lost upon further depletion of casein kinase1 (CK1g1), previously reported to phosphorylate CKBD. Thus, Cdc7, in conjunction with CK1g1, facilitates the interaction between Claspin and Chk1 through phosphorylating CKBD. We also show that, whereas Cdc7 is predominantly responsible for CKBD phosphorylation in cancer cells, CK1g1plays a major role in non-cancer cells, providing rationale for targeting Cdc7 for cancer cell-specific cell killing.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files.Figure 1-source data 1 has been provided for Figure 1AFigure 4 -source data 1-3 have been provided for Figure 4Figure 5-figure supplement 2-source data 1 has been provided for Figure 5-figure supplement 2Figure 5-figure supplement 3-source data 1 has been provided for Figure 5-figure supplement 3BFigure 6-source data 1has been provided for Figure 6BFigure 7-source data 1 has been provided for Figure 7BFigure 7-source data 2 has been provided for Figure 7D

Article and author information

Author details

  1. Chi-Chun Yang

    Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  2. Hiroyuki Kato

    Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  3. Mayumi Shindo

    Protein Analyses Laboratory, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
    Competing interests
    The authors declare that no competing interests exist.
  4. Hisao Masai

    Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
    For correspondence
    masai-hs@igakuken.or.jp
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1268-5302

Funding

Japan Society for the Promotion of Science (23247031)

  • Hisao Masai

Japan Society for the Promotion of Science (26251004)

  • Hisao Masai

Japan Society for the Promotion of Science (24114520)

  • Hisao Masai

Japan Society for the Promotion of Science (25125724)

  • Hisao Masai

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2019, Yang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,638
    views
  • 378
    downloads
  • 37
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chi-Chun Yang
  2. Hiroyuki Kato
  3. Mayumi Shindo
  4. Hisao Masai
(2019)
Cdc7 activates replication checkpoint by phosphorylating the Chk1 binding domain of Claspin in human cells
eLife 8:e50796.
https://doi.org/10.7554/eLife.50796

Share this article

https://doi.org/10.7554/eLife.50796

Further reading

    1. Chromosomes and Gene Expression
    2. Neuroscience
    Robyn D Moir, Emilio Merheb ... Ian M Willis
    Research Article

    Pathogenic variants in subunits of RNA polymerase (Pol) III cause a spectrum of Polr3-related neurodegenerative diseases including 4H leukodystrophy. Disease onset occurs from infancy to early adulthood and is associated with a variable range and severity of neurological and non-neurological features. The molecular basis of Polr3-related disease pathogenesis is unknown. We developed a postnatal whole-body mouse model expressing pathogenic Polr3a mutations to examine the molecular mechanisms by which reduced Pol III transcription results primarily in central nervous system phenotypes. Polr3a mutant mice exhibit behavioral deficits, cerebral pathology and exocrine pancreatic atrophy. Transcriptome and immunohistochemistry analyses of cerebra during disease progression show a reduction in most Pol III transcripts, induction of innate immune and integrated stress responses and cell-type-specific gene expression changes reflecting neuron and oligodendrocyte loss and microglial activation. Earlier in the disease when integrated stress and innate immune responses are minimally induced, mature tRNA sequencing revealed a global reduction in tRNA levels and an altered tRNA profile but no changes in other Pol III transcripts. Thus, changes in the size and/or composition of the tRNA pool have a causal role in disease initiation. Our findings reveal different tissue- and brain region-specific sensitivities to a defect in Pol III transcription.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Ting-Wen Chen, Hsiao-Wei Liao ... Chung-Te Chang
    Research Article

    The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.